Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Biopharm Drug Dispos. 2011 Sep 22;32(8):471–481. doi: 10.1002/bdd.770

Figure 7.

Figure 7

Change from baseline in urine CTX/creatinine following four IV doses of 0.25, 0.50, 1.0 and 2.0 mg of ibandronate every 3 months in postmenopausal women with osteopenia. Symbols represent mean data from the literature [8] and lines represent model-fitted profiles using the integrated bone homeostasis model.